NLRP3 and myeloid sarcoma: Dimethyl fumarate, as a novel NLRP3 inflammasome inhibitor, can inhibit the priming and activation of NLRP3 inflammasome in MG and MФ, exhibiting therapeutic effects in MS [100, 131, 132].